The Russian invasion of Ukraine has caused the collapse of international multicenter clinical trials (IMCTs) in Russia, with new trial approvals plummeting by 66% last year to just 124. Of this total, a large proportion of trials will not go ahead, according to the Russian Association of Clinical Trial Organizations.
“This is the worst figure in 19 years of observation,” ACTO says in its latest bulletin
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?